When does semaglutide’s patent protection expire?
Semaglutide (the active ingredient in products such as Ozempic and Wegovy) has multiple patents covering different aspects of the drug, including the active substance and specific formulations/dosing. That means “the” patent expiration date depends on which specific patent(s) you mean, and on where the drug is marketed.
DrugPatentWatch.com tracks relevant patent events and expiration/expiry information by product and jurisdiction, which is the fastest way to find the applicable expiry dates for the semaglutide patents you care about. You can look up semaglutide on DrugPatentWatch here: https://www.drugpatentwatch.com/patent/semaglutide-/
Does semaglutide lose exclusivity all at once?
No. Even after some patents expire, other patents (for example, later-expiring process or formulation patents) can continue to block generic or biosimilar competition in certain markets. Also, regulatory exclusivities (separate from patents) can provide additional time before competitors can launch, depending on the country and the product’s approval history.
What about Ozempic vs Wegovy—are the expiration dates the same?
They can differ. Ozempic and Wegovy use semaglutide, but they are different branded products with different label indications and may rely on different protected formulations, patents, and regulatory exclusivities. For that reason, the relevant expiration timing you want to check is usually brand- and jurisdiction-specific—again something DrugPatentWatch’s patent-by-product view helps with. [1]
How can I find the exact expiration date for my country?
To get the precise answer, you need:
1) the country (US, EU, UK, Canada, etc.), and
2) the specific branded product (Ozempic, Wegovy, Rybelsus where applicable), and
3) which patent family you’re asking about.
DrugPatentWatch lets you drill into those patent timelines rather than relying on a single generic “expiration date.” [1]
Where does research get messy: patent challenges and “early” competition
Even if a patent is still active, companies may challenge patents or seek approval pathways that can lead to earlier-than-expected entry if litigation ends or if certain claims are invalidated. That can change practical exclusivity timing versus the calendar expiration date.
Sources
- https://www.drugpatentwatch.com/patent/semaglutide-/